Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer

NCT00376623 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: BI 2536

Sponsor

Boehringer Ingelheim